INTRODUCTION
Renal cell carcinoma (RCC) is the most common cancer of the kidney (1) . RCC presents with metastatic disease in up to 30% of patients and recurrence develops in 40% of patients treated for a localized tumor (2) . Although RCC constitutes ,5% of adult malignancies, it is the sixth leading cause of cancer deaths worldwide because of the lack of effective therapy for advanced disease (1) . Metastatic RCC is a highly chemoresistant disease, and until 2005, immunotherapy was recommended as a first-line treatment. Rarely, immunotherapy, especially high-dose interleukin 2, can produce a complete response; however, this occurs only in highly selected patients, and the median overall survival (OS) was 1 year (3).
RCCs are highly vascularized tumors that overexpress a number of growth factors and their receptors, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and transforming growth factor secondary to the inactivation of the von Hippel -Lindau tumor suppressor gene (4, 5) . These ligands and receptors are involved in the autocrine stimulation of tumor cell growth, as well as the paracrine stimulation of neovascular or stromal fibroblast growth that supports tumor expansion (2, 5) . Thus, inhibitors or antagonists of these pathways [e.g. bevacizumab (6) , sorafenib (7) and sunitinib (8) ] have demonstrated marked anti-tumor activity in patients with advanced RCC, particularly those with the clear cell form of the disease.
Sunitinib malate (SUTENT w , Pfizer Inc., New York, NY, USA) is an oral, multitargeted tyrosine kinase inhibitor which acts on VEGF receptors 1 -3 (9), PDGF receptors (9,10) and KIT (10) . In the pivotal Phase III trial of patients with metastatic RCC, sunitinib demonstrated a significantly longer progression-free survival (PFS) time (11 vs. 5 months, P , 0.001) and a higher objective response rate (47% vs. 12%) than did interferon-a alone (8) . Sunitinib also showed a strong tendency toward prolonged OS (26.4 vs. 21.8 months, P ¼ 0.051) when compared with interferon-a alone, despite the crossover to sunitinib in 33% of patients with interferon-a after disease progression (11) . However, patients had to satisfy strict eligibility criteria that included good performance status, no serious co-morbidities and adequate organ function. In addition, only patients with clear cell histology were eligible for the study (8) . Although sunitinib has been universally prescribed to patients with advanced RCC, and authors have consistently noted a much higher incidence of toxicity, few studies have represented experience of daily clinical practice in patients of Asian ethnicity treated with sunitinib (12, 13) . Here, we assess the clinical efficacy and toxicity of sunitinib in Korean patients with advanced RCC. (14) .
PATIENTS AND METHODS

PATIENTS
TREATMENT
Sunitinib was administered orally (50 mg) once a day for 4 weeks, followed by a 2-week resting period (4/2 schedule). A dose reduction of sunitinib (to 37.5 or 25 mg) was allowed depending on the type and severity of adverse events. Shortly after sunitinib was prescribed, we experienced several cases of intolerability to the 4/2 schedule of sunitinib even after the doses were reduced to 37.5 or 25 mg daily. In these cases, we changed the administration schedule, so that patients received the reduced dose for two consecutive weeks followed by a 1-week rest period every 3 weeks (2/1 schedule) (15) , which seemed to improve the tolerability and compliance.
To prevent hand -foot syndrome, patients were advised to apply moisturizing lotion at least twice daily and to avoid inappropriate pressure on their hands and feet. Also, patients were instructed to maintain a blood pressure log.
SAFETY AND EFFICACY EVALUATION
Patients underwent a physical examination on day 1 of every treatment cycle. Complete blood cell counts and serum chemistry with electrolyte tests were performed on days 1 and 28 of each cycle. When the patients tolerated the treatment and their conditions were stable, laboratory tests were performed only on day 1 of each cycle. In the first cycle of treatment, physical examination and laboratory tests were also performed on day 14.
Hematologic and non-hematological adverse events were graded according to the NCT-CTCAE v.3.0 (16). The usual dose interruption or reduction scheme was used. If Grade 3 hematological toxicities occurred, the treatment was withheld until the recovery to Grade 2 or better, at which time sunitinib treatment was resumed at the same dose. In the case of Grade 4 hematological or Grade 3 -4 non-hematological toxicities, treatment was withheld until those patients achieved at least recovery Grade 2 or 1, respectively, after which time the dose was reduced (50 to 37.5 mg daily and 37.5 to 25 mg daily, respectively). When Grade 4 hematologic or Grade 3/4 non-hematologic toxicities recurred despite reduction to 25 mg sunitinib per day, treatment was usually discontinued and patients were treated with other agents, such as sorafenib or temsirolimus.
Computed tomography or magnetic resonance imaging was performed at baseline and every treatment cycle. Response was assessed using the response evaluation criteria in solid tumors (RECIST) (17) .
STATISTICAL ANALYSES
The analysis of safety and efficacy was performed only for patients who received sunitinib via the standard 4/2 schedule. Descriptive statistics were reported as proportions and medians. The time to progression (TTP) was measured from the first day of sunitinib treatment until disease progression.
If patients did not progress, they were censored at the time of the last follow-up. Time to treatment failure (TTTF) was defined as the time between the first day of treatment and the date of the first sign of failure of treatment, such as disease progression, discontinuation of treatment due to toxicity, patient refusal, loss to follow-up or death. OS was measured from the first day of treatment until death of any cause. If a patient was alive at the last follow-up, OS was determined at that time. The Kaplan -Meier estimates were used in the analysis of all time event variables, with differences between the curves analyzed using the log-rank test. SPSS Version 14.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analyses.
RESULTS
PATIENTS
A total of 77 patients were treated with sunitinib during the study period. Three patients were ineligible for this analysis due to concomitant active lung cancer (Stage IV), ECOG 4 associated with acute renal failure and malignant pericardial effusion and consolidative sunitinib therapy for 4 months after achieving complete remission after interleukin-2 therapy. Sunitinib (50 mg) was initially administered via a 4/2 schedule in 65 patients and a 2/1 schedule in 9 patients. The remaining analysis in this report is based on the 65 patients with the 4/2 schedule. Baseline characteristics are summarized in Table 1 .
EFFICACY
Of the 53 patients with measurable lesions, 23 (43%) achieved a confirmed partial response (PR), 23 (43%) had stable disease and 4 (8%) had progressive disease, whereas 3 (6%) could not be evaluated due to loss to follow-up. A waterfall plot of the changes in target lesions is depicted in Fig. 1 . Of the 15 patients with a measurable intact primary tumor or contralateral renal metastases, tumor shrinkage was observed in 9 (60%) patients with renal lesions. Of the 10 patients with non-clear cell histology, 4 (40%) patients achieved stable disease and 1 patient with papillary type histology achieved PR.
At the time of this analysis (September 2009), 57 patients had discontinued treatment and 34 patients were dead. The median follow-up duration of surviving patients were 26.8 months (range, 13.5 -40.1). The median TTP was 11.8 months [95% confidence interval (CI), 8.1 -15.4] and the median OS was 22.8 months (95% CI, 13.9 -31.6) with 1-year survival rates of 68% (Fig. 2) . The median TTTF was 7.0 months (95% CI, 4.8 -9.3). The most common causes of treatment withdrawal were disease progression (31 patients, 48%) and toxicity (15 patients, 23%). The reason for treatment discontinuation was not known in eight patients who were lost to follow-up.
Additional analyses were performed to examine clinicopathologic characteristics and the course of the disease. Differences in TTP and OS were not observed with respect to age (58 vs. .58 years), sex, histology (clear cell type vs. non-clear cell type) and history of prior immunotherapy. However, the MSKCC scoring system accurately predicted OS with 3-year survival rates of 76%, 57% and 21% in low-, intermediate-and high-risk group, respectively (P , 0.001). 
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DRUG EXPOSURE AND SAFETY
The median treatment duration for the 57 patients who discontinued treatment was 6.3 months. Of the 64 patients who continued the treatment for more than one cycle, dose reduction was necessary in 30 (46%) patients. The dose was decreased to 37.5 mg daily in 23 (35%) patients and decreased to 25 mg daily in 7 (11%) patients. Seven patients who did not tolerate the dose of 25 mg daily were received sunitinib-at the same dose or increased dose if tolerableusing the 2/1 schedule. The patient distribution with respect to the highest observed grade of toxicity is summarized in Table 2 . The most frequently reported hematologic toxicities were anemia, thrombocytopenia and leukopenia. In particular, Grade 3 or 4 thrombocytopenia occurred in 16% of patients. Although Grade 3 or 4 neutropenia developed in 7% of patients, none of them experienced a febrile reaction. The most frequent Grade 2 -3 non-hematologic toxicities were stomatitis, fatigue, hand -foot syndrome and anorexia.
Other non-hematologic adverse events with clinical relevance included decreased cognitive function (n ¼ 1, Grade 2), heart failure (n ¼ 1, Grade 3), gall bladder perforation (n ¼ 1, Grade 4) and ischemic colitis (n ¼ 1). Interestingly, six out of seven patients tolerated better to the same dose or even increased dose of sunitinib after changing the treatment schedule to 2/1.
DISCUSSION
Since a pivotal Phase III trial found that sunitinib was more effective than interferon-a, sunitinib has been generally considered a first-line treatment of choice for metastatic RCC (8, 11) . However, some have questioned whether the strict eligibility criteria of this Phase III trial allowed for the fair representation of general population with metastatic RCC (8) . Although a recently published expanded-access trial reported a profile similar to the previous Phase III trial, the safety and efficacy of sunitinib in the general population with metastatic RCC, especially patients of Asian ethnicity, have remained unclear (18) . Our retrospective study revealed the efficacy and safety of sunitinib in Korean patients with RCC who may be encountered in general clinical practice.
The efficacy results of the present study are consistent with previous western and Asian studies (8,11 -13,18) . The objective response rate for sunitinib was 43% and the disease control rate was 86%. In terms of time-related (23) 2 ( Other non-hematologic adverse events with clinical relevance were decreased cognitive function (n ¼ 1, Grade 2), heart failure (n ¼ 1, Grade 3), gall bladder perforation (n ¼ 1, Grade 4) and ischemic colitis (n ¼ 1). a Toxicity was not assessable in three patients who lost to follow-up. outcomes, the median TTP was 11.8 months, the median OS was 22.8 months and the 1-year survival rate was 68%. Given that 45% of the current study cohort consisted of patients with poor risk, according to the MSKCC scoring system, sunitinib seems to be equally effective in a broad RCC population with Asian ethnicity. Consistent with previous trials, the MSKCC risk criteria were also effective in predicting the prognosis of Asian RCC patients treated with sunitinib (11, 14) . Furthermore, sunitinib seemed to be effective in patients with RCC of non-clear cell histology. Although another study showed prolonged PFS in patients with metastatic papillary and chromophobe RCC who were treated with sunitinib, the number of patients was too small to draw definite conclusions about the efficacy of sunitinib in patients with non-clear cell RCC (19) . Prospective studies, one of which is currently being conducted at our institution, are needed to draw a firm conclusion (20) . Sunitinib was more toxic in our study population than in the previous Phase III trial. Dose reduction was required in 46% of the patients in our study, which is significantly higher than the previous Phase III trial (32%) and expanded-access trial (33%) (8, 18) . The most common adverse events were fatigue (81%), stomatitis (60%), thrombocytopenia (56%), anemia (55%) and hand -foot syndrome (48%), although these were mostly Grade 1 or 2 events. Grade 3 or 4 drug-related adverse events that lead to dose reduction or interruption occurred more frequently in this study than in previous trials (8, 11, 18) . Grade 3 or 4 events due to hand -foot syndrome, thrombocytopenia and stomatitis were more common in our study (16%, 16% and 10%, respectively) than in previous Phase III trials (5%, 8% and 1%, respectively). These higher toxicity profiles are consistent with a previous Korean retrospective study and Japanese Phase II trial which showed higher rates of Grade 3 or worse for hand -foot syndrome (9% and 14%, respectively) and thrombocytopenia (38% and 55%) (12, 13) . In addition, both studies showed high rates of dose reduction or interruption due to treatment-related adverse events (76% and 78%). Because these Asian studies including the current study have evaluated over 200 patients, and consistently suggested similar efficacy and higher incidence of toxicities compared with western trials, we feel that these should be considered meaningfully rather than neglected as anecdotal findings. Although these might reflect the distinction in patients' baseline characteristics (e.g. age, gender and body surface area), ethnic differences also might be an important determinant of sunitinib toxicity (21) . Similarly, Phase III trials of sorafenib, a similar anti-VEGF agent approved for RCC and hepatocellular carcinoma, also revealed ethnic discrepancies in toxicities related to hand -foot syndrome and diarrhea between Western and Asia-pacific regions (22, 23) . Genetic polymorphisms in pharmacokinetic and pharmacodynamic pathways have been suggested as the cause of this phenomenon (24, 25) . On the basis of these results, it seems necessary to evaluate another sunitinib administration strategy in Asian ethnicity that might decrease toxicity while preserving efficacy, as severe toxicity is usually related to poor compliance and dose interruption or reduction that may lead to insufficient responses (26) . A Phase I study of sunitinib administered for 2 weeks followed by 1 week of rest (i.e. a 3-week cycle) (15) yielded a favorable toxicity profile, which could be a clue to why our patients, who experienced intolerable toxicity to sunitinib with a 4/2 schedule, fared well to the same or increased doses of sunitinib after changing to a 2/1 schedule. Therefore, we are now conducting a randomized trial of sunitinib administration via a 4/2 vs. a 2/1 schedule in patients with advanced RCC.
In conclusion, sunitinib was effective and tolerated in Korean patients with advanced RCC in daily practice setting. Higher incidence of severe toxicities in this study is consistent to the results of previous Asian studies, although it must be interpreted with caution due to small population size and retrospective nature of this study. Further investigations for ethnic differences in toxicity profiles and new strategy to reduce toxicity without sacrificing efficacy are warranted in future trials.
